Top Health and Human Services official John Knox said that the U.S. is taking active steps to make sure active pharmaceutical ingredients are made in the U.S. and not in China.
“There’s a lot of levers that can be pulled and need to be used in order to bring onshoring back,” Knox said on the “Just the News, No Noise” TV show. “Over the past 50 years, we’ve offshored everything to China, especially, and now, with the president making the moves [and] using those tools available to him, he’s allowed manufacturers to actually step back into the space of coming back and onshoring medications.”
Knox serves as the Principal Deputy Assistant Secretary for Preparedness and Response at HHS.
Knox said that 70% of active pharmaceutical ingredients (APIs) and key materials are manufactured in China and India. He also said that about 90% of antibiotics are manufactured in China.
Earlier this month, President Donald Trump signed an executive order to fill up the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) with critical drug components in order to ensure a supply chain for critical medications.
“Restoring capacity for domestic production of essential pharmaceutical products is essential to safeguarding national health and security against global supply chain disruptions,” the White House said in a statement.
Click this link for the original source of this article.
Author: Ray Hilbrich
This content is courtesy of, and owned and copyrighted by, https://www.offthepress.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
